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The challenge of screening for 
asymptomatic rheumatic 
heart disease in South Africa
The Drakensberg Declaration, which arose out of the fi rst All 
Africa Workshop on Rheumatic Fever and Rheumatic Heart 
Disease in October 2005, has led to renewed activity on the 
epidemiology and prevention of rheumatic heart disease in 
many parts of Africa.(6) The focus of the action has been in 
four areas: awareness raising, conducting surveillance studies, 
advocacy, and promoting the establishment of national preven-
tion programmes (the A.S.A.P. programme).(7) The fi rst import-
ant work to emerge in the post-Drakensberg era has been 
the echocardiographic screening study of school children in 
Mozambique and Cambodia. This study has shown that the 
prevalence of rheumatic heart disease by echocardiography is 
over 10 times higher than that detected by auscultation (i.e., 30.2/
1 000 vs. 2.2/1 000 in Mozambique).(8) Almost all the cases of 
rheumatic heart disease detected in this and other screening 
studies were previously undiagnosed. These cases represent the 
tip of the iceberg of the burden of disease in the general popula-
tion because cases in school children represent 15-20% of all 
cases in the population.(9)
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ASYMPTOMATIC 
RHEUMATIC HEART 
DISEASE
Acute rheumatic fever and rheumatic heart disease remain 
major features of medical practice in South Africa. The burden 
of rheumatic heart disease at the population level was estimated 
for the fi rst time by Barlow and his team among 12 000 school 
children in Soweto in 1971.(1) This auscultatory screening study 
of asymptomatic school children reported an overall prevalence 
of 6.9 per 1 000, with a peak prevalence rate of 19.2/1 000 in older 
children. A decade later, there was a similar survey of 1 000 
school children in Inanda near Durban that found a lower 
prevalence of rheumatic heart disease of 1/1 000.(2) These 
fi ndings led to calls for the establishment of a national pro-
gramme for the prevention of rheumatic fever and rheumatic 
heart disease in South Africa.(1) The government responded 
appropriately by declaring acute rheumatic fever and the initial 
diagnosis of rheumatic heart disease as notifi able conditions 
in 1979.(3) The fi rst national guideline on the prevention of 
rheumatic fever and rheumatic heart disease at the primary 
care level was published in 1997.(4) These research, legislative, 
and policy making efforts have unfortunately met with little 
success mainly because of indifference and neglect on the part 
of medical practitioners and health administrators.(3,5)
Acute rheumatic fever and rheumatic heart disease 
remain common in the population of South Africa. A 
recent screening study of asymptomatic schoolchildren in 
Mozambique and Cambodia makes a compelling case for 
a shift in the approach to screening for rheumatic heart 
disease from auscultation to portable echocardiography. 
Rheumatic heart disease meets all the epidemiological 
criteria for screening in the South African population. 
The incorporation of echocardiographic screening pro-
grammes into the school health system and in antenatal 
clinics for the pre-symptomatic diagnosis of rheumatic 
heart disease could result in the reduction of morbidity and 
mortality through the early and wide application of 
secondary antibiotic prophylaxis. SAHeart 2009; 6:100-103
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A series of echocardiographic screening studies confi rm that 
rheumatic fever and rheumatic heart disease are of suffi cient 
importance to warrant the urgent attention of the international 
public health and research communities.(10-12) These echocardio-
graphic screening studies have major implications for clinical and 
public health practice in South Africa. These data raise questions 
on whether screening for asymptomatic rheumatic heart disease 
is required, how it should be conducted, what diagnostic criteria 
should be used, and the cost-effectiveness of screening for 
asymptomatic rheumatic heart disease. 
RATIONALÉ FOR SCREENING  ASYMPTOMATIC      
PEOPLE FOR RHEUMATIC HEART DISEASE
For a disease to be suitable for screening as a tool for prevention, 
it must satisfy the following conditions: (1) there must be evidence 
of a signifi cant burden of disease, (2) the condition must have 
an initial latent stage, (3) which can be detected by simple, 
accessible, sensitive and specifi c tests, and (4) there must be 
evidence that early intervention improves prognosis. It can be 
argued that rheumatic heart disease meets all the criteria for 
screening in many developing countries such as South Africa. 
There is evidence that the condition may affect up to 3% of 
school children; that large numbers of pre-symptomatic cases exist, 
that portable echocardiography is a sensitive tool for screening; 
and that the early introduction of penicillin prophylaxis prevents 
recurrent attacks of acute rheumatic fever.(1,8,13)
A 2002 report from a paediatric cardiology workshop highlights 
the belief among clinicians that South Africa continues to experi-
ence a high  burden of cases of symptomatic rheumatic heart 
disease.(5) Recent reports show that rheumatic heart disease is 
present in 1% of pregnant patients presenting to tertiary centres 
and is associated with high maternal morbidity and mortality 
and poor foetal outcomes.(14,15) 
Clinical and echocardiographic screening studies indicate that 
the overwhelming majority of cases (over 85%) with defi nite 
rheumatic heart disease are asymptomatic.(1,8,11,12) These observa-
tions indicate that the disease has a pre-symptomatic stage that 
can be detected by portable echocardiography and penicillin 
prophylaxis is available to prevent recurrent attacks of rheumatic 
fever and potentially ameliorate the development of chronic 
rheumatic heart disease. There is therefore a strong case to be 
made for the screening of the general population for rheumatic 
heart disease in South Africa and other countries where the 
disease remains endemic.
WHAT IS THE APPROPRIATE METHOD FOR                
SCREENING ASYMPTOMATIC PEOPLE FOR             
RHEUMATIC HEART DISEASE?
Several studies present a compelling argument for the use of 
portable echocardiography as the screening test of choice for 
asymptomatic individuals who are at high risk of rheumatic 
heart disease, as opposed to screening by cardiac auscultation.(8,11) 
If clinical diagnosis had been relied upon in the Mozambique 
study, approximately 90% of echocardiographically detected 
cases would have been missed.(8,10) In the Mozambican study, 
clinical examination underdiagnosed rheumatic heart disease 
more than 10 fold, whereas in the Tongan study, the opposite 
held in that junior auscultators overestimated rheumatic heart 
disease.(8,11) This variability in the performance of cardiac auscul-
tation in screening probably refl ects differences in the clinical 
skill and experience of the clinicians, a factor that is not likely to 
improve in an era of over-reliance on technology and tests in 
clinical medicine.
The time has come to replace the stethoscope with portable 
cardiac ultrasound in screening for rheumatic heart disease.(16-18) 
The cost of portable ultrasound equipment is falling and the 
technical capability of these devices is improving. There is 
therefore a need to increase the availability and use of portable 
echocardiography in endemic regions of the world. In addition 
the feasibility of training a large number of local healthcare 
workers in basic echocardiography to screen for rheumatic 
heart disease should be investigated.
DIAGNOSTIC CRITERIA FOR RHEUMATIC HEART 
DISEASE IN ASYMPTOMATIC INDIVIDUALS
Until now, the diagnosis of rheumatic heart disease in asympto-
matic individuals has been based on the detection of patho-
logical murmur in combination with typical echocardiographic 
morphological changes and functional abnormalities (e.g., Doppler 
regurgitation or stenosis) of the heart valves. The patients with 
no history of acute rheumatic fever nor a clinically audible 
murmur but who have typical structural and functional abnor-
malities of rheumatic heart disease on echocardiography are 
regarded as probable rheumatic heart disease. Individuals with 
isolated Doppler regurgitation on echocardiography with no 
history of rheumatic fever, no audible murmur, and no structural 
valve abnormality are regarded as possible rheumatic heart 
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disease. The natural history of possible and probable rheumatic 
heart disease (i.e., subclinical rheumatic heart disease) is not 
known.(17) In addition, it is not known whether penicillin pro-
phylaxis is indicated in subjects with subclinical rheumatic heart 
disease.(19) The World Health Organisation, however, recom-
mends antibiotic prophylaxis for those with “signifi cant” sub-
clinical rheumatic mitral regurgitation, who are defi ned on the 
basis of the following echocardiographic criteria: (1) the presence 
of a colour jet of more than 1 centimetre in length, (2) that 
is evident in at least two imaging planes, (3) with the mosaic jet 
having a peak velocity of greater than 2.5 metres per second, and 
that the Doppler signal is holosystolic.(19,20) The WHO criteria 
differentiates physiological from pathological regurgitation, but 
these criteria do not cover many of the morphological changes 
seen in chronic rheumatic heart disease. Investigators in the 
A.S.A.P. programme propose to use an amalgamation of the 
WHO criteria with the fi ndings of Viyashlaskmi and others to 
detect defi nite, probable and possible disease on screening 
echocardiograms.(20) This approach allows the classifi cation of 
cases into defi nite, probable and possible rheumatic heart 
disease using criteria that consider all possible functional and 
structural abnormalities that are associated with rheumatic fever 
and rheumatic heart disease (Tables 1 and 2).
COST-EFFECTIVENESS OF  SCREENING FOR             
ASYMPTOMATIC RHEUMATIC HEART DISEASE
There is good evidence that primary prevention (i.e., treatment 
of suspected streptococcal pharyngitis with penicillin) and second-
ary prophylaxis (i.e., regular intramuscular penicillin injections) 
for rheumatic fever are cost-effective interventions for the 
control of rheumatic heart disease.(13,21) Secondary prophylaxis 
is best delivered as part of a register-based control programme, 
providing education and enabling better clinical follow-up.(22) 
It is not known, however, whether the use of portable 
echocardiography to screen asymptomatic people in rheumatic 
heart disease-endemic regions is cost-effective.(23) The major 
costs are related to staff, equipment, and other health service 
costs of community-based screening. One way of reducing the 
costs related to screening may be to integrate rheumatic heart 
disease screening with the existing school health system and 
antenatal care services for school children and pregnant 
women, the two high-risk groups who may be targeted initially.
CONCLUSION                                                                  
It is clear from the new evidence on the superior performance 
and high yield of echocardiographic screening of rheumatic heart 
disease in high-risk communities that we cannot continue with 
“business as usual” in the management of rheumatic heart 
disease in South Africa.(24) First, healthcare practitioners in 
South Africa need to be reminded that rheumatic fever is a 
notifi able condition and be encouraged to develop registry-
based follow-up clinics for their patients with rheumatic heart 
ASYMPTOMATIC RHEUMATIC HEART DISEASE
TABLE 1:  Proposed echocardiographic diagnostic criteria for 
rheumatic heart disease used in screening studies of asymptomatic 
participants without a history of rheumatic fever
Defi nite RHD
Signifi cant mitral stenosis (mean gradient: >4mmHg)
Signifi cant structural and/or functional changes involving both mitral and aortic 
valves, i.e., multiple valve disease
Probable RHD
Signifi cant structural and functional changes involving either mitral or aortic 
valves, i.e., single valve disease
Possible RHD
Isolated structural OR functional changes involving either mitral or 
aortic valve
TABLE 2:  Defi nitions of Structural and Functional changes in 
rheumatic heart disease
Defi nitions
Signifi cant structural changes: 
Thickness of mitral and aortic leafl ets 
greater than 4mm
Increased echogenicity of submitral 
structures
Rheumatic nodules giving a beaded 
appearance
Prolapse of mitral, aortic or tricuspid 
valves
Reduced mobility of leafl ets
Chordal tears 
Elbow or dog leg deformity of the 
anterior mitral valve leafl et.
Fixed or markedly restricted motion 
of the posterior mitral leafl et
Signifi cant functional changes: 
Signifi cant mitral regurgitation:
defi ned as a mitral regurgitant jet at 
least 1 cm from the coaptation point 
of the valve leafl ets, seen in two planes, 
high velocity (mosaic pattern) and 
persisting throughout systole. Addi-
tional changes that may be present 
include multiple regurgitant jets and/or 
a posterolaterally-directed jet
Signifi cant aortic regurgitation: 
defi ned as an aortic regurgitant jet at 
least 1 cm from the coaptation point 
of the valve leafl ets, of high velocity 
(mosaic pattern) and seen in two 
planes
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disease.(3,22) These two simple interventions would go a long 
way towards documenting the burden and temporal trends of 
acute rheumatic fever and rheumatic heart disease in the 
country, and ensuring that all patients with the disease are in 
secure secondary prophylaxis programmes. There are too few 
cases that are reported, which has contributed in part to the 
neglect of rheumatic heart disease as an important public health 
problem.(3,25) Second, we need to consider the incorporation of 
echocardiographic screening for rheumatic heart disease in the 
schools and antenatal clinics of South Africa. The auscultatory 
and echocardiographic fi ndings of screening can be transmitted 
to clinical cardiology centres for reporting by trained staff.  The 
possibility of using technologists, nurses or even local community 
health care workers to perform a focused echocardiogram with 
specialised staff reviewing these echocardiograms should be 
explored.(23)  With the shortages in trained staff in all strata 
of healthcare, we need to develop innovative and creative 
strategies for the implementation of effective screening program-
mes in resource-poor settings. The A.S.A.P. programme provides 
an evidence-based framework for building a national pro-
gramme of prevention of rheumatic heart disease in South 
Africa and other African countries.(7) Finally, prospective studies 
are required to evaluate the natural history and management 
of subclinical rheumatic heart disease, and to explore cost-
effective strategies for the screening of rheumatic heart disease 
in the general population of South Africa.  
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